Neximmune announces preclinical research collaboration with columbia university irving medical center's herbert irving comprehensive cancer center

Gaithersburg, md., april 26, 2022 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today announced a preclinical research collaboration with columbia university irving medical center's (cuimc) herbert irving comprehensive cancer center (hiccc). the research will focus on the use of neximmune's adoptive cell therapy, aim act, in columbia's patient-derived organoid (pdo) models of hpv-associated cancers, including head and neck squamous cell carcinoma. columbia scientists hiroshi nakagawa, md, associate professor of medicine, and brian henick, md, assistant professor of medicine, will lead the research. dr. anil rustgi, director of hiccc, will join drs. nakagawa and henick in the investigations. hiccc is an nci designated cancer center that is at the forefront of discovery science, translational medicine, clinical trials, clinical care and community outreach.
NEXI Ratings Summary
NEXI Quant Ranking